Shingrix vs Arexvy
A side-by-side look at two vaccine medications advertised on TV. Informational only — not medical advice.
| US Shingrix | US Arexvy | |
|---|---|---|
| Generic name | recombinant zoster vaccine | respiratory syncytial virus vaccine |
| Drug class | Recombinant Adjuvanted Vaccine | Recombinant Adjuvanted Vaccine |
| Treats | Shingles prevention | RSV prevention in older adults |
| Category | Vaccine | Vaccine |
| Manufacturer | GSK | GSK |
| Year approved | 2017 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $150M | $110M |
| Common side effects | Sore arm, Muscle pain, Fatigue, Headache | Injection site pain, Fatigue, Muscle pain, Headache |
Frequently asked questions
Is Shingrix or Arexvy better?
Neither is universally "better." Shingrix (recombinant zoster vaccine) and Arexvy (respiratory syncytial virus vaccine) are both used for vaccine, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Shingrix and Arexvy?
Shingrix is a Recombinant Adjuvanted Vaccine made by GSK, while Arexvy is a Recombinant Adjuvanted Vaccine made by GSK. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Shingrix has the larger estimated TV advertising budget of the two.